Bristol-Myers Squibb Co (BMY) Shares Sold by People s United Financial Inc.

People s United Financial Inc. trimmed its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 7.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,662 shares of the biopharmaceutical company’s stock after selling 11,093 shares during the period. People s United Financial Inc.’s holdings in Bristol-Myers Squibb were worth $8,232,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of BMY. CSat Investment Advisory L.P. bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth approximately $113,000. Cypress Capital Management LLC WY raised its position in shares of Bristol-Myers Squibb by 154.7% during the third quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 1,160 shares during the period. Landaas & Co. WI ADV acquired a new position in shares of Bristol-Myers Squibb during the second quarter worth approximately $131,000. CLS Investments LLC raised its position in shares of Bristol-Myers Squibb by 194.3% during the third quarter. CLS Investments LLC now owns 2,575 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 1,700 shares during the period. Finally, Selective Wealth Management acquired a new position in shares of Bristol-Myers Squibb during the third quarter worth approximately $184,000. Hedge funds and other institutional investors own 72.74% of the company’s stock.

A number of equities analysts have recently weighed in on the company. BMO Capital Markets lowered their target price on Bristol-Myers Squibb to $56.00 and set a “market perform” rating on the stock in a research report on Tuesday, November 27th. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, November 27th. Societe Generale set a $47.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Wednesday, November 14th. Morgan Stanley lowered their target price on Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday, November 6th. Finally, Wolfe Research assumed coverage on Bristol-Myers Squibb in a research report on Tuesday, October 23rd. They set an “outperform” rating and a $66.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $61.73.

NYSE BMY opened at $53.69 on Tuesday. The firm has a market capitalization of $87.26 billion, a P/E ratio of 17.84, a P/E/G ratio of 1.49 and a beta of 1.11. Bristol-Myers Squibb Co has a 12 month low of $46.94 and a 12 month high of $70.05. The company has a quick ratio of 1.40, a current ratio of 1.53 and a debt-to-equity ratio of 0.41.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.18. The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. Equities analysts expect that Bristol-Myers Squibb Co will post 3.87 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Co (BMY) Shares Sold by People s United Financial Inc.” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.com-unik.info/2018/12/04/bristol-myers-squibb-co-bmy-shares-sold-by-people-s-united-financial-inc.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

See Also: Do stock splits help investors?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit